Receptor-binding Domain-associated Serotypes of SARS-CoV-2

Overview

Journal Emerg Microbes Infect

Specialty Infectious Diseases

Date 2024 Jan 24

PMID 38264798

Authors

Zezhong Liu

Lu Lu

Shibo Jiang

Affiliations

Soon will be listed here.

References

Hu S, Wu C, Wu X, Ma X, Shu C, Chen Q . Classification of five SARS-CoV-2 serotypes based on RBD antigenicities. Sci Bull (Beijing). 2023; 68(23):3003-3012. DOI: 10.1016/j.scib.2023.09.048. View

Dai L, Zheng T, Xu K, Han Y, Xu L, Huang E . A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS. Cell. 2020; 182(3):722-733.e11. PMC: 7321023. DOI: 10.1016/j.cell.2020.06.035. View

Liu Z, Zhou J, Xu W, Deng W, Wang Y, Wang M . A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs. Cell Res. 2022; 32(3):269-287. PMC: 8767042. DOI: 10.1038/s41422-022-00612-2. View

He Y, Zhou Y, Liu S, Kou Z, Li W, Farzan M . Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochem Biophys Res Commun. 2004; 324(2):773-81. PMC: 7092904. DOI: 10.1016/j.bbrc.2004.09.106. View

Tan T, Rijal P, Rahikainen R, Keeble A, Schimanski L, Hussain S . A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses. Nat Commun. 2021; 12(1):542. PMC: 7822889. DOI: 10.1038/s41467-020-20654-7. View

Tan C, Zhu F, Chia W, Young B, Yeoh A, Althaus T . Distinctive serotypes of SARS-related coronaviruses defined by convalescent sera from unvaccinated individuals. Hlife. 2024; 1(1):26-34. PMC: 11238253. DOI: 10.1016/j.hlife.2023.07.002. View

He Y, Lu H, Siddiqui P, Zhou Y, Jiang S . Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. J Immunol. 2005; 174(8):4908-15. DOI: 10.4049/jimmunol.174.8.4908. View

Liu Z, Zhou J, Wang X, Xu W, Teng Z, Chen H . A pan-sarbecovirus vaccine based on RBD of SARS-CoV-2 original strain elicits potent neutralizing antibodies against XBB in non-human primates. Proc Natl Acad Sci U S A. 2023; 120(11):e2221713120. PMC: 10242718. DOI: 10.1073/pnas.2221713120. View

Wang Q, Iketani S, Li Z, Liu L, Guo Y, Huang Y . Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell. 2022; 186(2):279-286.e8. PMC: 9747694. DOI: 10.1016/j.cell.2022.12.018. View

10.

Du L, He Y, Zhou Y, Liu S, Zheng B, Jiang S . The spike protein of SARS-CoV--a target for vaccine and therapeutic development. Nat Rev Microbiol. 2009; 7(3):226-36. PMC: 2750777. DOI: 10.1038/nrmicro2090. View

11.

Carreno J, Alshammary H, Tcheou J, Singh G, Raskin A, Kawabata H . Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Nature. 2022; 602(7898):682-688. DOI: 10.1038/s41586-022-04399-5. View

12.

Wang X, Sun L, Liu Z, Xing L, Zhu Y, Xu W . An engineered recombinant protein containing three structural domains in SARS-CoV-2 S2 protein has potential to act as a pan-human coronavirus entry inhibitor or vaccine antigen. Emerg Microbes Infect. 2023; 12(2):2244084. PMC: 10424610. DOI: 10.1080/22221751.2023.2244084. View

13.

Zhao X, Li D, Ruan W, Chen Z, Zhang R, Zheng A . Effects of a Prolonged Booster Interval on Neutralization of Omicron Variant. N Engl J Med. 2022; 386(9):894-896. PMC: 8809506. DOI: 10.1056/NEJMc2119426. View

14.

Liu Z, Xu W, Chen Z, Fu W, Zhan W, Gao Y . An ultrapotent pan-β-coronavirus lineage B (β-CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope. Protein Cell. 2021; 13(9):655-675. PMC: 8458794. DOI: 10.1007/s13238-021-00871-6. View